However, it should be emphasized that an involvement of the other β-AR subtypes in the observed effects related to melanoma progression cannot be excluded, owing to the broad dosage spectrum with which propranolol and other β-ARs antagonists have been used in clinical practice [95], and considering that a clear-cut selectivity remains questionable for most β-blockers [96]. The gene discussed is ADRB2; the disease is melanoma.